Literature DB >> 11843211

Multicentric reticulohistiocytosis.

F B Luz1, N Kalil-Gaspar, M Ramos-e-Silva.   

Abstract

BACKGROUND: Multicentric reticulohistiocytosis (MR) is a rare histiocytic systemic disease mainly affecting the skin and synovia.
OBJECTIVE: To present the main and newest aspects of MR.
METHOD: A review of the current medical literature, composing a retrospective study of 96 case reports published world-wide since 1977.
RESULTS: Facial and hand skin nodules with symmetric arthritis were the most frequent clinical presentation. The pathognomonic sign of'coral beads' and vermicular erythematous lesions bordering nostrils, seems to be very characteristic of MR. There is a significant association with cancer. Histiocytic cells of MR are best characterized on immunohistochemistry by its immunoreactivity for vimentin, CD68 and CD45 and non-reactivity for S-100 protein, CD34 and factor XIIIa. Although the outcome of the disease is usually very limiting for the patients, treatment with immunosuppressive drugs may be useful.
CONCLUSION: MR is a unique histiocytic proliferative disease with a peculiar immunophenotypic pattern and distinctive clinical and histopathological aspects.

Entities:  

Mesh:

Year:  2001        PMID: 11843211     DOI: 10.1046/j.1468-3083.2001.00362.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  18 in total

Review 1.  Multicentric reticulohistiocytosis: a critical review.

Authors:  Carlo Selmi; Adam Greenspan; Arthur Huntley; M Eric Gershwin
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

2.  Erythema, papules, and arthralgia associated with liver cancer: report of a rare case of multicentric reticulohistiocytosis.

Authors:  Liang Hu; Jun-Hua Mei; Jin Xia; Quan-Shui Hao; Li-Ping Cheng; Yao-Hua Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Targetable driver mutations in multicentric reticulohistiocytosis.

Authors:  Norihiro Murakami; Tomohisa Sakai; Eisuke Arai; Hideki Muramatsu; Daisuke Ichikawa; Shuji Asai; Yoshie Shimoyama; Naoki Ishiguro; Yoshiyuki Takahashi; Yusuke Okuno; Yoshihiro Nishida
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

Review 4.  Multicentric reticulohistiocytosis: a rare yet challenging disease.

Authors:  Arshia D Islam; Stanley M Naguwa; Gurtej S Cheema; John C Hunter; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 5.  Multicentric reticulohistiocytosis: case report with response to infliximab and review of treatment options.

Authors:  Cristina C Macía-Villa; Antonio Zea-Mendoza
Journal:  Clin Rheumatol       Date:  2014-04-15       Impact factor: 2.980

6.  A Rare Case of Multicentric Reticulohistiocytosis with Concurrent Rheumatoid Arthritis.

Authors:  Anupama Behera; Sujata Devi; Satyabrata Guru; Madhusmita Sethy
Journal:  Cureus       Date:  2019-08-24

7.  Multicentric reticulohistiocytosis associated with rheumatoid arthritis.

Authors:  Daichi Hoshina; Tadamichi Shimizu; Riichiro Abe; Junko Murata; Koichi Tanaka; Hiroshi Shimizu
Journal:  Rheumatol Int       Date:  2005-03-12       Impact factor: 2.631

8.  Microarray analysis reveals the inhibition of nuclear factor-kappa B signaling by aristolochic acid in normal human kidney (HK-2) cells.

Authors:  Ya-yin Chen; Su-yin Chiang; Hsiu-ching Wu; Shung-te Kao; Chien-yun Hsiang; Tin-yun Ho; Jaung-geng Lin
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

9.  Malignancy-associated multicentric reticulohistiocytosis.

Authors:  Boutros El-Haddad; Dalia Hammoud; Timothy Shaver; Shadi Shahouri
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

10.  Papular xanthomas and erosive arthritis in a 3 year old girl, is this a new MRH variant?

Authors:  Catalina Matiz; Polly J Ferguson; Andrea Zaenglein; Brandt Groh; Catherine April Bingham
Journal:  Pediatr Rheumatol Online J       Date:  2009-10-08       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.